Neuroscience Catalyst is a public-private partnership between the University of Toronto, Janssen Inc. and the Johnson & Johnson Innovation center in California to fund collaborative, open-source, pre-competitive, early-stage proof of concept research towards identifying and validating new therapeutic targets that can progress to the clinical treatment for mood disorders and Alzheimer’s disease. Neuroscience Catalyst was designed with the aim of leveraging the collective skills and resources of academia and industry to accelerate the pace of developing and bringing new neuroscience drugs to market and providing treatments for major brain disorders.